Navigation Links
Neurobiological Technologies' CEO to Retire on December 31, 2008
Date:7/7/2008

EMERYVILLE, Calif., July 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. The Company expects Mr. Freiman to continue to serve on the Board. Mr. Freiman is the former chief executive officer of Syntex Corporation of Palo Alto, California.

Mr. Freiman is retiring after 11 years of service to the company. "Paul's strong leadership has helped grow our company to where we have a Phase 3 program in a highly underserved acute ischemic stroke market and his contributions with XERECEPT(R) and Memantine to our organization will be long- lasting. We thank him for his dedicated service and wish him the best as he moves on to the next chapter in his life," said Abraham E. Cohen, NTI's chairman of the Board of Directors.

Mr. Freiman stated, "Since I stepped into the role of an interim CEO in 1997, I have enjoyed all aspects of my time at NTI. I remain committed to our principal product, Viprinex(TM), which may provide an extraordinary opportunity in the treatment of acute ischemic stroke. I have announced my intent so that the Board of Directors has sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active NTI director beyond my retirement."

A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva North America, to search for a new CEO and has engaged the services of a retained search firm.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Neurobiological Technologies Sets Date for Third Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Sets Date for Research and Development Day
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
9. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
10. Neurobiological Technologies Sets Date for Second Quarter Financial Results
11. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... LabRoots , the leading provider of scientific ... the world, is announcing a new textbook scholarship, the second scholarship in the LabRoots ... 17 years or older, pursuing a degree in one of the life sciences. The ...
(Date:5/24/2017)... ... May 23, 2017 , ... Triumph ... modular buildings, announced the launch of the Mobile Big Room. This state-of-the-art ... help support on-site teamwork and collaboration. , The Mobile Big Room enables ...
(Date:5/24/2017)... 2017 As Ebola resurfaces in the ... 20 suspected cases now reported, a new analysis of the ... a correlation between the 2014 and 2017 outbreaks of the ... in 2012-13, which preceded the 2014 outbreak. An analysis of ... Replikin counts in 2014-15, which again precedes the current outbreak ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... for research and the development of cardiac regeneration therapies. The development of ... of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of CM ...
Breaking Biology Technology:
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
Breaking Biology News(10 mins):